Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
Open Access
- 25 September 2012
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (41) , 16642-16647
Abstract
The deregulation of the epidermal growth factor receptor (EGFR) has a significant role in the progression of tumors. Despite the development of a number of EGFR-targeting agents that can arrest tumor growth, their success in the clinic is limited in several tumor types, particularly in the highly malignant glioblastoma multiforme (GBM). In this study, we generated and characterized EGFR-specific nanobodies (ENb) and imageable and proapoptotic ENb immunoconjugates released from stem cells (SC) to ultimately develop a unique EGFR-targeted therapy for GBM. We show that ENbs released from SCs specifically localize to tumors, inhibit EGFR signaling resulting in reduced GBM growth and invasiveness in vitro and in vivo in both established and primary GBM cell lines. We also show that ENb primes GBM cells for proapoptotic tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Furthermore, SC-delivered immunoconjugates of ENb and TRAIL target a wide spectrum of GBM cell types with varying degrees of TRAIL resistance and significantly reduce GBM growth and invasion in both established and primary invasive GBM in mice. This study demonstrates the efficacy of SC-based EGFR targeted therapy in GBMs and provides a unique approach with clinical implications.Keywords
This publication has 33 references indexed in Scilit:
- Mesenchymal stem cells engineered for cancer therapyAdvanced Drug Delivery Reviews, 2012
- Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomasNature Neuroscience, 2011
- The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradationProceedings of the National Academy of Sciences, 2010
- A Novel Molecule Integrating Therapeutic and Diagnostic Activities Reveals Multiple Aspects of Stem Cell-based TherapyStem Cells, 2010
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapyClinical and Experimental Immunology, 2009
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFRCancer Research, 2009
- Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapyProceedings of the National Academy of Sciences, 2009
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomasNeuro-Oncology, 2008
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005